TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
New and emerging approaches for chronic spontaneous urticaria (CSU) were discussed at an American Academy of Dermatology meeting, including medicines targeting BTK, IL-4 receptors and c-KIT. Brian Kim said phase III data for remibrutinib in three forms of chronic inducible urticaria were reported, but the source does not provide results or establish how the emerging treatments compare.
New drug targets for chronic hives were a focus at an American Academy of Dermatology (AAD) meeting, with discussion spanning BTK inhibition, IL-4 receptor blockade and c-KIT strategies. In a video recorded after the meeting, dermatologist Brian Kim of the Icahn School of Medicine at Mount Sinai described developments for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), including phase III data for remibrutinib in three CIndU forms; the report does not provide the trial results themselves.
Kim identified remibrutinib, a BTK inhibitor, as a major topic in the CSU session. The report describes it as recently approved for CSU. Kim also said phase III data had been reported for the drug in three types of CIndU: dermatographism, cold urticaria and cholinergic urticaria. The source does not give the size of those studies, their outcomes, or whether the data were presented as a conference abstract or in a publication.
Kim also pointed to dupilumab, which blocks the IL-4 receptor, as a continuing topic in CSU. He connected interest in the medicine to its range of type 2 inflammation-related indications in dermatology. The meeting report does not specify a new CSU result for dupilumab or provide details about its use in this condition.
A third area is c-KIT inhibition. Kim discussed barzolvolimab, describing it as a drug that inhibits c-KIT and may also deplete mast cells. He also disclosed that he co-founded Alys Pharma, which is developing a c-KIT inhibitor using a bispecific strategy intended to target c-KIT on mast cells. That program is a company development, not evidence in the report that the approach is effective or available to patients.
More Targets, Different Treatment Strategies
The discussion points to a wider set of biological targets being explored for CSU and CIndU. Rather than relying on one mechanism, the approaches described include BTK inhibition, IL-4 receptor blockade and interference with c-KIT and mast cells. That may matter to patients whose hives persist or whose symptoms fall into different inducible categories, although the meeting report does not show which patients might benefit from each approach.
The potential reach extends beyond CSU. Kim cited remibrutinib data across three CIndU types, while the broader session included both spontaneous and inducible disease. Still, the available account is a summary of a physician’s remarks, not a head-to-head comparison or a treatment guideline. It offers no response rates, safety findings, or evidence that one target is superior to another.
For readers, the key distinction is between a treatment described as approved for CSU and approaches or indications still being discussed in development. The source calls remibrutinib recently approved, but does not identify the approving regulator or approval date. It provides no approval status for barzolvolimab in CSU or the Alys Pharma program.
chronic hives treatment medications
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The AAD Session and Its Focus
The remarks came from a CSU session at an AAD meeting in Denver, Colorado. Kim said it was only the second CSU session held at the AAD meeting to that point, following an earlier meeting session. The video was recorded after the April meeting and the MedPage Today report was published on October 8, 2026.
The session covered both CSU and chronic inducible urticaria. CSU refers to chronic hives that occur spontaneously, while CIndU involves hives triggered by particular stimuli. The report’s examples are dermatographism, cold urticaria and cholinergic urticaria. This distinction helps explain why discussion of multiple targets and disease types featured in the session, but the source does not provide diagnostic or treatment guidance.
Kim’s comments combine discussion of clinical development and an industry disclosure. He identified his connection to Alys Pharma while describing its c-KIT program. That interest is relevant when weighing the comments about the company’s approach; the report does not independently assess the program.
““They’ve reported really great phase III data in chronic inducible urticaria””
— Brian Kim, MD
As an affiliate, we earn on qualifying purchases.
Trial Results and Approval Status
The report does not supply the phase III results Kim referenced for remibrutinib in CIndU: there are no response figures, trial sizes, safety details or follow-up periods. It also does not identify where or when those data were released. Readers cannot use this account alone to judge the treatment’s performance in the three conditions.
The source gives limited detail about barzolvolimab and other c-KIT approaches, including no trial outcomes or development timelines. Kim’s statement that barzolvolimab may deplete mast cells is his description of its proposed action, not a clinical outcome reported in this article. The Alys Pharma bispecific strategy is also described without evidence or a timeline.
Although the report calls remibrutinib recently approved for CSU, it does not specify the regulator or date. It does not establish whether dupilumab is approved for CSU, nor provide a new result for it. The comparative benefits, risks and appropriate use of these treatments remain outside the information provided.
As an affiliate, we earn on qualifying purchases.
Evidence Needed From Ongoing Research
The next useful developments would be fuller reporting of the remibrutinib phase III data in dermatographism, cold urticaria and cholinergic urticaria, including trial methods, outcome measures and safety findings. That information would clarify what Kim meant by “really great” data and how the results may relate to people with those forms of CIndU.
Further clinical evidence will also be needed to establish the effectiveness and safety of c-KIT-targeting treatments, including barzolvolimab and the bispecific approach described by Kim. The source provides no expected dates for results, regulatory decisions or treatment availability. It also does not identify a next milestone for dupilumab in CSU.
Until more details are reported, the meeting discussion signals expanding research directions rather than a complete change in care. Patients should discuss treatment decisions with a qualified health professional; this report does not determine which option is appropriate for an individual.
As an affiliate, we earn on qualifying purchases.
Key Questions
What treatments and targets were discussed?
The AAD session covered remibrutinib, a BTK inhibitor; dupilumab, which blocks the IL-4 receptor; and c-KIT strategies including barzolvolimab. The report does not compare their effectiveness.
What forms of inducible urticaria were included?
Kim said phase III data for remibrutinib had been reported in dermatographism, cold urticaria and cholinergic urticaria. The article does not provide the trial results or detailed methods.
Is barzolvolimab available as a treatment?
The source discusses barzolvolimab as a c-KIT inhibitor but does not state that it is approved or available for CSU. It provides no regulatory status or treatment timeline.
What did the report say about Alys Pharma?
Kim disclosed that he co-founded Alys Pharma and said it has a c-KIT inhibitor using a bispecific strategy intended to target c-KIT on mast cells. The report gives no clinical results or development timeline for that program.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
